Alps Advisors Inc. Invests $263,000 in Vaxart, Inc. (NASDAQ:VXRT)

Alps Advisors Inc. purchased a new position in shares of Vaxart, Inc. (NASDAQ:VXRTGet Rating) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 75,014 shares of the biotechnology company’s stock, valued at approximately $263,000. Alps Advisors Inc. owned about 0.06% of Vaxart as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of VXRT. Financial Engines Advisors L.L.C. bought a new position in Vaxart in the 1st quarter valued at about $50,000. Y Intercept Hong Kong Ltd bought a new position in Vaxart in the 2nd quarter valued at about $37,000. Western Wealth Management LLC bought a new position in Vaxart in the 1st quarter valued at about $58,000. Fox Run Management L.L.C. bought a new position in Vaxart in the 1st quarter valued at about $58,000. Finally, WINTON GROUP Ltd grew its position in Vaxart by 50.3% in the 1st quarter. WINTON GROUP Ltd now owns 16,975 shares of the biotechnology company’s stock valued at $86,000 after buying an additional 5,681 shares in the last quarter. Institutional investors own 35.15% of the company’s stock.

Vaxart Trading Down 4.4 %

NASDAQ:VXRT opened at $1.30 on Thursday. Vaxart, Inc. has a twelve month low of $1.26 and a twelve month high of $8.13. The company has a 50-day moving average of $1.80 and a 200-day moving average of $2.94. The firm has a market cap of $170.62 million, a price-to-earnings ratio of -1.57 and a beta of 0.80.

Analyst Upgrades and Downgrades

VXRT has been the subject of a number of recent analyst reports. Cantor Fitzgerald decreased their target price on shares of Vaxart from $11.00 to $8.00 and set an “overweight” rating for the company in a research report on Friday, September 2nd. Brookline Capital Management reiterated a “buy” rating on shares of Vaxart in a research report on Monday, October 3rd.

Vaxart Profile

(Get Rating)

Vaxart, Inc, a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection.

Featured Stories

Institutional Ownership by Quarter for Vaxart (NASDAQ:VXRT)

Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.